Full Press Release Details
NEW BRUNSWICK, N.J. , May 18, 2016 /PRNewswire/ -- At a meeting today with the investment community, senior leaders from the Johnson & Johnson Family of Companies (NYSE: JNJ ) will review strategies and opportunities for growth in the Consumer and Medical Device segments. The company will highlight the strategic advantages of its broad base in human health care, its holistic approach to innovation and its strategy to achieve above-market growth across the enterprise.
"The way we are approaching innovation goes beyond products and services," said Alex Gorsky , Chairman and CEO of Johnson & Johnson. "We are innovating how we go to market, how we reach new consumers, and how we use technology to drive better outcomes and deliver long-term value to patients, consumers and customers around the world."
Today's meeting will also feature new insight into the company's increased focus on leading in the Health-Tech space – the intersection between health care and technology. Johnson & Johnson is creating new engagement models, building a more flexible and secure digital business, and developing smarter products.
"We have the right internal capabilities, and are developing strategic partnerships in health care technology, to reshape the way health care is delivered, managed and experienced," said Gorsky.
Medical Devices
Johnson & Johnson has the world's most comprehensive Medical Devices business, with $25.1 billion in total sales for 2015, driven by 11 $1 billion -plus platforms. Johnson & Johnson competes in the estimated $370 billion global Medical Devices market, including hospital medical devices in the Surgery, Orthopaedics and Cardiovascular and Specialty Surgery categories, and in the consumer-facing medical device categories of Vision Care and Diabetes Care.
In its hospital medical device businesses, the company holds global leadership positions in Surgery and Orthopaedics, as well as key regional leadership positions in China and other emerging markets. With plans to file more than 20 major new products through 2018, expanding its global presence and implementing novel commercial models, the company expects to deliver above-market growth within the next year. The business is also continuing to accelerate its pace of innovation, and estimates its current pipeline of products – expected to be filed for regulatory approval by 2018 – has greater than $6 billion in sales potential.
The company's consumer medical device businesses have leading positions and are poised for growth. Johnson & Johnson Vision Care, the global market leader in contact lenses, expects to grow market share and exceed the industry pace of innovation by delivering two new products per year through 2020. The Johnson & Johnson Diabetes Care Companies, market leading in blood glucose monitoring, are increasing their competitiveness and expect improved market penetration globally to reach more patients. Combined, these businesses have a robust innovation agenda with a current pipeline of products expected to be filed for regulatory approval by 2018, with sales potential greater than $2 billion .
The Johnson & Johnson Consumer business competes in categories that total $350 billion globally, and those categories are growing at a weighted average of more than 4 percent. The business has three $1 billion brands today, and expects to expand that to five $1 billion brands by 2020.
The Consumer segment is well positioned to grow sales above the market, while continuing to expand margins to achieve benchmark levels of profitability. With its focus on science-based, professionally endorsed products, the Consumer business expects to accelerate growth with a differentiated innovation pipeline, including more than 100 new products this year.
About Today's Meeting
The meeting will be webcast starting at 9 a.m. EDT today and can be accessed along with full copies of the presentations and speaker biographies via the Johnson & Johnson Investor Relations website: www.investor.jnj.com . A replay and podcast will be available approximately two hours after the live webcast. A live Twitter feed for today's meeting is accessible via #JNJ16BR.
Users of the Johnson & Johnson Investor Relations mobile app for the iPad® and iPhone® mobile digital devices can also access the event. This free app is available in the iTunes® store and includes stock information, news releases, company information, webcasts, SEC filings, and the company's pharmaceutical product pipeline, among other information.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Cautions Concerning Forward-Looking Statements
iPad, iPhone and iTunes are trademarks of Apple Inc.
SOURCE Johnson & Johnson